BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 18, 2002
View Archived Issues
Euroscreen acquires license to hormone receptor technology
Read More
Orally active VEGFR tyrosine kinase inhibitor RWJ-417975 exerts antitumor activity in mouse models
Read More
Improved HIV protease inhibitors discovered at Merck & Co.
Read More
Histamine H3 receptor agonist discovered by European team
Read More
Clinical trials of drugs in development for neurological disorders presented in Denver
Read More
New clinical trial results with mitoxantrone reported at this week's AAN meeting
Read More
Clinical trials with botulinum toxins reported at the AAN meeting
Read More
Prolifix identifies hydroxamate-based inhibitors of HDAC with antitumor activity
Read More
VEGFR tyrosine kinase inhibitor enters clinical testing based on preclinical results
Read More
Xcytrin to enter confirmatory phase III trial in lung cancer patients
Read More
Human Genome Sciences updates achievements in first quarter of 2002
Read More
Patient treatment begun in phase I/IIa trial of ZYC-300
Read More
Discovery Partners and Xenon Genetics collaborate on metabolic syndrome drug discovery
Read More
Consensus awarded SBIR grant for AIDS drug development
Read More
Trial initiated for Reolysin in prostate cancer
Read More
AGIX-4207 I.V. well tolerated and safe in phase I trial
Read More
Phase III trial of high-dose Betaferon/Betaseron planned
Read More
Biogen launches long-term study comparing Avonex and Rebif in MS
Read More
NDA submitted for Eligard 30 mg for advanced prostate cancer
Read More
New bicyclic alphavbeta3 and/or alphavbeta5 antagonists under study at Pharmacia
Read More
Agents for cardiovascular disorders developed at Sanofi-Synthelabo
Read More
Pola identifies compounds that reverse multidrug resistance in cancer and infections
Read More
Dual adenosine A1 and A2A receptor antagonists and their use described in recent patent
Read More
GSK presents new series of potent and selective COX-2 inhibitors
Read More
Recent patent describes synthesis, activity and use of polyamine AMPA receptor antagonists
Read More